Acepodia
Executives
View the org chart displaying its 5 main executives
Most searched biographies at Acepodia
- Sonny Hsiao, Co-Founder, President and Chief Executive Officer
- Patrick Yang, Co-Founder and Chairman of the Board
- Jessica Lee, Head of Business Development
Create your alert
to follow the executive moves at Acepodia.
Biotechnology
Acepodia has 2,345 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Genus (United Kingdom (UK)).
Popular M&A news in Biotechnology
- Purespring Therapeutics has just announced a $105 Million fundraising (posted on March 14 2025).
- Bristol-Myers Squibb has announced the acquisition of 2Seventy Bio (posted on March 11 2025).
- Callio Therapeutics has just announced a $187 Million fundraising (posted on March 7 2025).
Popular contacts in Biotechnology
News
Press releases by Acepodia
- Acepodia Announces 2025 Clinical Development Milestones and Comprehensive Growth Strategies-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Announced CEO Dr. Sonny Hsiao’s Appointment as Chairman and Extraordinary Shareholders’ Meeting Agenda-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in IgG4-Related Disease
- Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
- Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkin's Lymphoma
- Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
- Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor
- Acepodia Announces Emerging Stock Listing on The Taipei Exchange-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER
- Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with Antibody-Cell Conjugation (ACC) Platform
- Acepodia Announces First Patient Dosed in Phase 1 Clinical Trial of ACE1831, an Anti-CD20 Armed Allogeneic Gamma Delta T-cell Therapy in Development to Treat Patients with Non-Hodgkin's Lymphoma
- View more press releases Close
Social media about Acepodia
- Acepodia on Wikipedia, Google News & Yahoo Finance
- Acepodia on LinkedIn, Twitter & YouTube
